Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa

AIDS Research and Human Retroviruses

Volumn 24, Issue 9, 2008, Pages 1225-1228

  Caron, Mélanie ^a   Makuwa, Maria ^a   Souquière, Sandrine ^a   Descamps, Diane ^b   Brun Vézinet, Françoise ^b   Kazanji, Mirdad ^a,c,d  

^a CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

^b BICHAT HOSPITAL   (France)

^c Service de Cooperation et d'Action Culturelle   (Gabon)

^d INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MANGANESE;

ADULT; ARTICLE; BLOOD SAMPLING; CENTRAL AFRICA; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MINER; MOSAICISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROPREVALENCE; VIRUS LOAD; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GABON; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; SEROEPIDEMIOLOGIC STUDIES;

EID: 51849145184     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0097     Document Type: Article

References (16)

1. Kantor R, Katzenstein DA, Efron B, et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2(4):e112.
2. WHO UNAIDS/WHO: Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections Gabon 2006. WHO UNAIDS/WHO Global HIV/AIDS Online Database, EFS 2006.
3. Vergne L, Malonga-Mouellet G, Mistoul I, et al.: Resistance to antiretroviral treatment in Gabon: Need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002;29(2):165-168.
4. Clift S, Anemona A, Watson-Jones D, et al.: Variations of HIV and STI prevalences within communities neighbouring new goldmines in Tanzania: Importance for intervention design. Sex Transm Infect 2003;79(4):307-312.
5. Murray J, Sonnenberg P, Nelson G, et al.: Effect of HIV on work-related injury rates in South African gold miners. AIDS 2005;19(17):2019-2024.
6. Heywood M: Mining industry enters a new era of AIDS prevention. Eye witness: South Africa. AIDS Anal Afr 1996;6(3):16.
7. Jung M, Agut H, Candotti D, Ingrand D, Katlama C, and Huraux JM: Susceptibility of HIV-1 isolates to zidovudine: Correlation between widely applicable culture test and PCR analysis. J Acquir Immune Defic Syndr 1992;5(4):359-364.
8. Larder BA, Kellam P, and Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991;5(2):137-144.
9. Nijhuis M, Boucher CA, Schipper P, Leitner T, Schuurman R, and Albert J: Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci USA 1998;95(24):14441-14446.
10. Shafer RW, Rhee SY, Pillay D, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21(2):215-223.
11. Corbett EL, Charalambous S, Moloi VM, et al.: Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004;170(6):673-679.
12. Pandrea I, Robertson DL, Onanga R, et al.: Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon. AIDS Res Hum Retroviruses 2002;18(15):1103-1116.
13. Njouom R, Pasquier C, Sandres-Sauné K, Harter A, Souyris C, and Izopet J: Assessment of HIV-1 subtyping for Cameroon strains using phylogenetic analysis of pol gene sequences. J Virol Methods 2003;110(1):1-8.
14. Toni TD, Recordon-Pinson P, Minga A, et al.: Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Cìte d'Ivoire: ANRS 1257 study. AIDS Res Hum Retroviruses 2003;(8):713-717.
15. Marechal V, Jauvin V, Selekon B, et al.: Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: A 2005 study. AIDS Res Hum Retroviruses 2006;22(10):1036-1044.
16. Vessière A, Nerrienet E, kfutwah A, et al.: HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaoundé, Cameroon. J Acquir Immune Defic Syndr 2006;42(2):256-258.